Neuronetics, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
STIM Nasdaq 3840 neurostar.com/neuronetics

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Neuronetics, Inc.

Neuronetics Appoints Robert Greene as Senior Vice President Sales - Jun 2nd, 2026 2:30 pm
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026 - Jun 2nd, 2026 6:32 am
Lungpacer Medical Appoints Steven Pfanstiel as Chief Financial Officer - Jun 1st, 2026 5:00 am
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment - May 14th, 2026 6:32 am
Neuronetics Q1 Earnings Call Highlights - May 5th, 2026 3:07 pm
Neuronetics, Inc. Q1 2026 Earnings Call Summary - May 5th, 2026 2:55 pm
Neuronetics (STIM) Q1 2026 Earnings Transcript - May 5th, 2026 2:20 pm
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates - May 5th, 2026 7:15 am
Neuronetics Reports First Quarter 2026 Financial and Operating Results - May 5th, 2026 5:50 am
How The Neuronetics (STIM) Investment Story Is Evolving With A Reset Price Target - May 2nd, 2026 8:14 am
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 29th, 2026 2:30 pm
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call - Apr 21st, 2026 6:30 am
How The Neuronetics (STIM) Investment Story Is Reset As Analysts Rework Valuation Assumptions - Apr 18th, 2026 5:07 am
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners - Apr 13th, 2026 6:32 am
Neuronetics Comments on Letter from Pointillist Family Office - Apr 7th, 2026 5:00 am
Neuronetics Announces Chief Financial Officer Transition - Apr 6th, 2026 2:30 pm
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business - Apr 6th, 2026 2:05 pm
How The Neuronetics (STIM) Story Is Shifting As Analysts Rework Valuation Assumptions - Apr 3rd, 2026 2:12 am
Neuronetics, Inc. Q4 2025 Earnings Call Summary - Mar 17th, 2026 10:46 am
Neuronetics (STIM) Q4 2025 Earnings Transcript - Mar 17th, 2026 9:02 am